We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
 TATAA Biocenter and Douglas Scientific Announce Tumor Cell Profiling Study Contest
News

TATAA Biocenter and Douglas Scientific Announce Tumor Cell Profiling Study Contest

 TATAA Biocenter and Douglas Scientific Announce Tumor Cell Profiling Study Contest
News

TATAA Biocenter and Douglas Scientific Announce Tumor Cell Profiling Study Contest

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of " TATAA Biocenter and Douglas Scientific Announce Tumor Cell Profiling Study Contest "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Douglas Scientific is sponsoring a Tumor Cell Profiling Study for up to three researchers as part of a collaborative partnership with TATAA Biocenter, recognized global experts in the field of high-performance qPCR and single-cell expression profiling. To enter, submit a brief description of your research proposal and study goals by July 27, 2015. 

The winners can choose up to eight assays for a variety of gene transcripts to be performed on a maximum of 94 cDNA samples. The assays can be selected from the GrandPerformance Panel of over 100 highly optimized expression assays for cancer cells developed by TATAA Biocenter, with testing conducted in Array Tape on the sensitive IntelliQube® qPCR instrument from Douglas Scientific. The IntelliQube, is the first fully automated instrument that features the seamless integration of liquid handling, thermal cycling, detection, and data analysis into a single unit. 

TATAA GrandPerformance qPCR assays are optimized for utmost sensitivity and specificity to measure expression profiles in individual cancer cells. All assays are probe based and validated in preamplification workflow allowing the profiling of up to 96 markers in each cell. The assays have been selected to be particularly relevant for the profiling of circulating tumor cells and cancer stem cells. “The combination of our GrandPerformance assays and the IntelliQube offers a previously unmet seamless workflow for high throughput profiling of individual cells,” says Mikael Kubista, TATAA Biocenter, CEO. “Single cell biology is emerging as one of the hottest research areas and the IntelliQube will become a preferred platform for the community.” 

“TATAA’s experience and reputation is unsurpassed when it comes to qPCR and gene expression analysis. It was a natural fit for us to work together,” said Ross Higgins, Business Development Executive with Douglas Scientific. “Their excitement for the IntelliQube affirms that we have delivered a very disruptive solution to the qPCR space. This contest is a small step forward in our company’s mission to partner with great scientists to make the world a better place.”

Advertisement